Predicta Biosciences

Executive Summary

Predicta Biosciences is a precision diagnostics company pioneering a cellular liquid biopsy platform for blood cancers and autoimmune diseases. Its flagship product, GenoPredicta™, leverages whole genome sequencing (WGS) of cells from bone marrow and blood to deliver comprehensive genomic characterization earlier and more accurately than traditional methods. By replacing invasive bone marrow biopsies and limited FISH testing, GenoPredicta aims to transform disease monitoring and treatment decisions for conditions like multiple myeloma. The platform's non-invasive approach and ability to detect subtle genomic changes position it as a potential standard-of-care upgrade in hematologic oncology and autoimmune disease management. The company is based in San Diego and operates in the early-stage private sector, focusing on clinical validation and regulatory strategy. If successful, GenoPredicta could address a significant unmet need for precise, non-invasive diagnostics that enable earlier intervention and personalized therapy. However, as a private company with no disclosed revenue or regulatory approvals, Predicta faces typical risks of technology adoption, clinical trial outcomes, and funding requirements. The next 12-18 months will be critical for demonstrating clinical utility and securing partnerships or capital to scale. Overall, Predicta represents a promising but early-stage opportunity in the precision diagnostics space.

Upcoming Catalysts (preview)

• Q4 2026Initial Clinical Validation Data for GenoPredicta in Multiple Myeloma60% success
• Q3 2026Series B Financing Round70% success
• Q2 2027Strategic Partnership with Major Oncology Center40% success